Vanguard Group’s Nektar Therapeutics NKTR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $43.4M | Buy |
1,027,089
+78,442
| +8% | +$4.39M | ﹤0.01% | 2237 |
|
|
2025
Q3 | $54M | Buy |
948,647
+219,155
| +30% | +$7.25M | ﹤0.01% | 2115 |
|
|
2025
Q2 | $18.9M | Sell |
729,492
-91,154
| -11% | -$1.02M | ﹤0.01% | 2585 |
|
|
2025
Q1 | $8.37M | Sell |
820,646
-1,222
| -0.1% | -$16K | ﹤0.01% | 2944 |
|
|
2024
Q4 | $11.5M | Sell |
821,868
-52,852
| -6% | -$932K | ﹤0.01% | 2880 |
|
|
2024
Q3 | $17.1M | Buy |
874,720
+10,220
| +1% | +$195K | ﹤0.01% | 2666 |
|
|
2024
Q2 | $16.1M | Buy |
864,500
+61,224
| +8% | +$1.29M | ﹤0.01% | 2670 |
|
|
2024
Q1 | $11.3M | Buy |
803,276
+418
| +0.1% | +$4.38K | ﹤0.01% | 2893 |
|
|
2023
Q4 | $6.8M | Sell |
802,858
-1,218
| -0.2% | -$9.22K | ﹤0.01% | 3155 |
|
|
2023
Q3 | $7.18M | Buy |
804,076
+330
| +0% | +$3.18K | ﹤0.01% | 3083 |
|
|
2023
Q2 | $6.93M | Sell |
803,746
-510,150
| -39% | -$5.44M | ﹤0.01% | 3147 |
|
|
2023
Q1 | $13.9M | Sell |
1,313,896
-223,822
| -15% | -$6.77M | ﹤0.01% | 2765 |
|
|
2022
Q4 | $52.1M | Sell |
1,537,718
-6,612
| -0.4% | -$320K | ﹤0.01% | 2168 |
|
|
2022
Q3 | $74.1M | Buy |
1,544,330
+170,649
| +12% | +$10.2M | ﹤0.01% | 1974 |
|
|
2022
Q2 | $78.3M | Buy |
1,373,681
+78,322
| +6% | +$4.94M | ﹤0.01% | 1962 |
|
|
2022
Q1 | $105M | Buy |
1,295,359
+61,232
| +5% | +$9.06M | ﹤0.01% | 1911 |
|
|
2021
Q4 | $250M | Buy |
1,234,127
+93,576
| +8% | +$20.3M | 0.01% | 1470 |
|
|
2021
Q3 | $307M | Buy |
1,140,551
+6,848
| +0.6% | +$1.65M | 0.01% | 1312 |
|
|
2021
Q2 | $292M | Buy |
1,133,703
+19,448
| +2% | +$5.38M | 0.01% | 1371 |
|
|
2021
Q1 | $334M | Buy |
1,114,255
+29,416
| +3% | +$9.16M | 0.01% | 1236 |
|
|
2020
Q4 | $277M | Buy |
1,084,839
+29,254
| +3% | +$7.56M | 0.01% | 1260 |
|
|
2020
Q3 | $263M | Sell |
1,055,585
-44,472
| -4% | -$14M | 0.01% | 1095 |
|
|
2020
Q2 | $382M | Sell |
1,100,057
-1,355
| -0.1% | -$423K | 0.01% | 888 |
|
|
2020
Q1 | $295M | Buy |
1,101,412
+24,238
| +2% | +$7.5M | 0.01% | 900 |
|
|
2019
Q4 | $349M | Sell |
1,077,174
-111,380
| -9% | -$32.3M | 0.01% | 1027 |
|
|
2019
Q3 | $325M | Sell |
1,188,554
-45,631
| -4% | -$16.7M | 0.01% | 1027 |
|
|
2019
Q2 | $659M | Buy |
1,234,185
+23,746
| +2% | +$11.9M | 0.02% | 680 |
|
|
2019
Q1 | $610M | Sell |
1,210,439
-9,863
| -0.8% | -$5.84M | 0.02% | 700 |
|
|
2018
Q4 | $602M | Sell |
1,220,302
-41,208
| -3% | -$24.9M | 0.03% | 626 |
|
|
2018
Q3 | $1.15B | Buy |
1,261,510
+44,060
| +4% | +$37.6M | 0.05% | 459 |
|
|
2018
Q2 | $892M | Buy |
1,217,450
+68,829
| +6% | +$79.4M | 0.04% | 545 |
|
|
2018
Q1 | $1.83B | Buy |
1,148,621
+161,134
| +16% | +$208M | 0.08% | 262 |
|
|
2017
Q4 | $885M | Buy |
987,487
+33,922
| +4% | +$20.1M | 0.04% | 534 |
|
|
2017
Q3 | $343M | Buy |
953,565
+19,572
| +2% | +$6.12M | 0.02% | 926 |
|
|
2017
Q2 | $274M | Buy |
933,993
+26,794
| +3% | +$7.74M | 0.01% | 1023 |
|
|
2017
Q1 | $319M | Buy |
907,199
+42,314
| +5% | +$9.51M | 0.02% | 915 |
|
|
2016
Q4 | $159M | Buy |
864,885
+92,247
| +12% | +$18.8M | 0.01% | 1325 |
|
|
2016
Q3 | $199M | Sell |
772,638
-4,060
| -0.5% | -$1.05M | 0.01% | 1112 |
|
|
2016
Q2 | $166M | Buy |
776,698
+20,083
| +3% | +$4.49M | 0.01% | 1173 |
|
|
2016
Q1 | $156M | Buy |
756,615
+58,889
| +8% | +$11.3M | 0.01% | 1174 |
|
|
2015
Q4 | $176M | Buy |
697,726
+17,301
| +3% | +$3.56M | 0.01% | 1091 |
|
|
2015
Q3 | $112M | Buy |
680,425
+17,607
| +3% | +$3.11M | 0.01% | 1354 |
|
|
2015
Q2 | $124M | Buy |
662,818
+80,001
| +14% | +$13.8M | 0.01% | 1374 |
|
|
2015
Q1 | $96.2M | Buy |
582,817
+29,187
| +5% | +$6M | 0.01% | 1530 |
|
|
2014
Q4 | $129M | Buy |
553,630
+12,302
| +2% | +$2.63M | 0.01% | 1244 |
|
|
2014
Q3 | $98M | Buy |
541,328
+2,645
| +0.5% | +$506K | 0.01% | 1366 |
|
|
2014
Q2 | $104M | Sell |
538,683
-4,455
| -0.8% | -$788K | 0.01% | 1370 |
|
|
2014
Q1 | $98.7M | Buy |
543,138
+41,309
| +8% | +$8.18M | 0.01% | 1352 |
|
|
2013
Q4 | $85.4M | Buy |
501,829
+32,271
| +7% | +$5.2M | 0.01% | 1420 |
|
|
2013
Q3 | $73.6M | Buy |
469,558
+14,622
| +3% | +$2.7M | 0.01% | 1450 |
|
|
2013
Q2 | $78.8M | Buy |
+454,936
| New | +$69.8M | 0.01% | 1325 |
|
Other funds holding NKTR
BI
TSC
AC
PM
SI
Vanguard Group's NKTR Position: Q4 2025 in Review
Vanguard Group increased its Nektar Therapeutics (NKTR) stake by 8.3% in Q4 2025, buying an estimated $4.39M and bringing the position to 1,027,089 shares worth $43.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2237.
Vanguard Group first reported a position in NKTR in Q2 2013 and has held it in 51 quarters since. The position peaked at $1.83B in Q1 2018. 180 funds tracked by Wall St. Rank hold NKTR as of Q4 2025.
- Vanguard Group held 1,027,089 shares of Nektar Therapeutics worth $43.4M as of Q4 2025.
- Vanguard Group bought 78,442 Nektar Therapeutics shares in Q4 2025, an estimated $4.39M.
- Nektar Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2237 holding.
- Vanguard Group first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 51 quarters since.
- Vanguard Group's Nektar Therapeutics position peaked at $1.83B in Q1 2018.
- 180 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.